appliedclinicaltrialsonline9h
Bexicaserin Produces Significant Seizure Reduction in PACIFIC OLE Trial for Developmental and Epileptic Encephalopathies
The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...
‘We could be just 10 years from a £10 test to catch dementia before it develops’
Our grey matter has always been a mystery, even to neurologists, but Professor Masud Husain says life-changing advances may ...
rheumatologyadvisor10h
An Introduction to Digital Therapy for Chronic Pain Management
Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new sophistication. The management of chronic pain in general is now being broadly ...
Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
precisionmedicineonline5h
Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...